Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myokardia Inc    MYOK

MYOKARDIA INC (MYOK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
49.1(c) 50.375(c) 50(c) 48.8(c) 49.6(c) Last
150 740 183 631 117 647 132 536 134 172 Volume
-1.31% +2.60% -0.74% -2.40% +1.64% Change
More quotes
Financials (USD)
Sales 2018 28,6 M
EBIT 2018 -63,7 M
Net income 2018 -55,4 M
Finance 2018 245 M
Yield 2018 -
Sales 2019 18,8 M
EBIT 2019 -36,8 M
Net income 2019 -106 M
Finance 2019 282 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 53,8x
EV / Sales2019 79,8x
Capitalization 1 782 M
More Financials
Company
MyoKardia, Inc. is a biopharmaceutical company.It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.The company focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result... 
More about the company
Surperformance© ratings of Myokardia Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYOKARDIA INC
04/06MYOKARDIA : Announces Appointment of Taylor C. Harris as Chief Financial Officer
AQ
04/05MYOKARDIA : Announces Appointment of Taylor C. Harris as Chief Financial Officer
AQ
04/04MYOKARDIA, INC. (NASDAQ : MYOK) Files An 8-K Departure of Directors or Certain O..
AQ
04/04MYOKARDIA INC : Change in Directors or Principal Officers, Regulation FD Disclos..
AQ
04/04MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Office..
GL
04/03MYOKARDIA : Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten i..
AQ
04/02MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten ..
GL
03/15MYOKARDIA : Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-H..
AQ
03/12MYOKARDIA : to Present at the Cowen and Company 38th Annual Health Care Conferen..
AQ
03/10MYOKARDIA : Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-H..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/21$MYOK - Zacks: Analysts Expect MyoKardia #MYOK Will Post Earnings of -$0.28 P.. 
04/21Zacks: Analysts Expect MyoKardia $MYOK Will Post Earnings of -$0.28 Per Share.. 
04/18Want the latest upgrades & downgrades for $EXP $IIIN $ECL $MYOK $CRME? Ch.. 
04/18Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia.. 
04/16$MYOK - Goldman Sachs Group Inc. Purchases 3,292 Shares of MyoKardia #MYOK  
More tweets
Qtime:137
News from SeekingAlpha
04/05YOUR DAILY PHARMA SCOOP : Tenax Surges, Eli Lilly's CYRAMZA, Cellectics Public O.. 
04/04New finance chief at MyoKardia 
04/03YOUR DAILY PHARMA SCOOP : MediciNova Makes A Strong Comeback, Alkermes' Setback,.. 
04/02MyoKardia commences mid-stage study of mavacantem in non-obstructive HCM 
03/10YOUR DAILY PHARMA SCOOP : Immuron Surges, MyoKardia Results, Voyager Reports Lon.. 
Chart MYOKARDIA INC
Duration : Period :
Myokardia Inc Technical Analysis Chart | MYOK | US62857M1053 | 4-Traders
Technical analysis trends MYOKARDIA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 72,2 $
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
June Lee Chief Operating Officer
Taylor C. Harris Chief Financial Officer
Marc Semigran Chief Medical Officer
Michael P. Graziano Vice President-Research Biology
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA INC17.81%1 782
GILEAD SCIENCES3.91%96 094
VERTEX PHARMACEUTICALS6.47%40 153
REGENERON PHARMACEUTICALS-15.99%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998